🔗 Permalink

Inventor profile of:

Klaus DUGI

City:

Dresden

Country:

Germany

Published Applications:

21

Last publication date:

2022-10-27

Top Assignees for applications by Klaus DUGI

The entities that hold a legal rights for patent applications filed by inventor DUGI Klaus:

BOEHRINGER INGELHEIM INTERNATIONAL GMBH 13 Ingelheim am Rhein, Germany
Ajinomoto Co., Inc. 3 Tokyo, Japan
BOEHRINGER INGELHEIM INTERNATIONAL GMBH 3 Ingelheim, Germany
NEUROSEARCH A/S 1 Ballerup, Denmark

Recent patent applications by DUGI Klaus

Klaus DUGI from Dresden, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2022-10-27

US20220340575A1

Chemistry; metallurgy

Use of a DPP-4 inhibitor in SIRS and/or sepsis

#2 | 2019-07-04

US20190202833A1

Chemistry; metallurgy

USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS

#3 | 2016-02-04

US20160030385A1

Human necessities

COMBINATION THERAPY WITH SGLT-2 INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS

#4 | 2016-01-07

US20160000798A1

Human necessities

USES OF DPP IV INHIBITORS

#5 | 2014-09-18

US20140274890A1

Human necessities

Treatment for diabetes in patients inappropriate for metformin therapy

#6 | 2014-05-15

US20140135348A1

Human necessities

Uses of DPP IV inhibitors

#7 | 2013-12-26

US20130345262A1

Human necessities

METHOD FOR PREVENTION OF STROKE

#8 | 2013-11-14

US20130303554A1

Chemistry; metallurgy

USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS

#9 | 2013-08-01

US20130196898A1

Human necessities

Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin

#10 | 2013-04-18

US20130096076A1

Human necessities

PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR

#11 | 2011-12-08

US20110301182A1

Human necessities

Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor

#12 | 2011-10-27

US20110263493A1

Human necessities

Treatment for diabetes in patients inappropriate for metformin therapy

#13 | 2011-08-11

US20110195917A1

Human necessities

Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate

#14 | 2011-04-28

US20110098240A1

Human necessities

PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR

#15 | 2011-03-17

US20110065731A1

Human necessities

Uses of DPP-IV inhibitors

#16 | 2010-12-16

US20100317575A1

Human necessities

PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE

#17 | 2009-07-16

US20090181905A1

Chemistry; metallurgy

Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments

#18 | 2009-01-15

US20090018159A1

Human necessities

Treatment of type 2 diabetes

#19 | 2007-12-06

US20070281940A1

Human necessities

Uses of DPP-IV inhibitors

#20 | 2007-10-18

US20070244176A1

Chemistry; metallurgy

Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments

#21 | 2007-03-29

US20070072813A1

Human necessities

Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives

InventorID:

198753 ⎘